Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to engineer a tri-specific antibody-based molecule that sti...

Full description

Bibliographic Details
Main Authors: Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
immune checkpoint inhibitor
t-cell stimulation
cancer immunotherapy
trispecific antibodies
fusion protein
antibody fragment
xenograft model
non-human primate
Online Access:http://dx.doi.org/10.1080/2162402X.2021.2004661

Internet

http://dx.doi.org/10.1080/2162402X.2021.2004661

Similar Items